CSIMarket Company Name, Ticker, Competitors, else..
 
Senti Biosciences Inc   (NASDAQ: SNTI)
Other Ticker:  
 
 
Price: $3.6800 $0.17 4.843%
Day's High: $3.73 Week Perf: -4.79 %
Day's Low: $ 3.43 30 Day Perf: -7.77 %
Volume (M): 19 52 Wk High: $ 7.25
Volume (M$): $ 71 52 Wk Avg: $2.27
Open: $3.70 52 Wk Low: $0.21



 Market Capitalization (Millions $) 17
 Shares Outstanding (Millions) 5
 Employees 27
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -67
 Cash Flow (TTM) (Millions $) -41
 Capital Exp. (TTM) (Millions $) 12

Senti Biosciences Inc
Senti Biosciences Inc is a biotechnology company that specializes in developing synthetic biology platforms for advancing healthcare solutions. They focus on engineering cell and gene therapies to cure a variety of diseases by programming cells to detect and respond to specific signals within the body. Their innovative technology allows for precise control over cellular behaviors, enabling targeted therapies with enhanced safety and efficacy. Senti Biosciences Inc aims to revolutionize the field of medicine by harnessing the power of synthetic biology to create personalized treatments for patients.


   Company Address: 2 Corporate Drive, First Floor South San Francisco 94080 CA
   Company Phone Number: 239-2030   Stock Exchange / Ticker: NASDAQ SNTI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADAP   -36.33%    
ATRA   -7.53%    
BEAM   -4.98%    
CRBU        1.96% 
GILD   -4.61%    
MGTX   -3.94%    
• View Complete Report
   



Clinical Study

Innovative Frontiers in Cancer Immunotherapy Senti Bios Groundbreaking Clinical Trials for Hepatocellular Carcinoma ...

Published Sun, Dec 29 2024 7:57 PM UTC

The landscape of cancer treatment is undergoing a transformative evolution as innovative therapies harness the immune system s capabilities. With an increasing emphasis on personalized medicine and cellular therapies, Senti Biosciences, Inc. is at the forefront of these advancements. Recent news highlights two promising developments from the company: the initiation of a clin...
Shares

Senti Biosciences Fortifies Talent Pool With Stock Options Amid Strategic Shift,

Published Wed, Dec 4 2024 1:00 AM UTC

Senti Biosciences Announces Employee Inducement Grants Amid Strategic RestructuringIn a move aimed at bolstering its workforce, Senti Biosciences, Inc. (Nasdaq: SNTI), a pioneering clinical-stage biotechnology firm, has announced the issuance of stock options to new employees. The announcement came on December 3, 2024, marking a significant step in the company s strategic e...
Shares

Senti Bio Boosts Share Value with Reverse Stock Split: Shares to Begin Trading on a Split-Adjusted Basis on July 18, 2024.

Published Tue, Jul 16 2024 12:30 PM UTC

Senti Bio Announces Reverse Stock Split: Shares Expected to Begin Trading on Split-Adjusted Basis on July 18, 2024
Senti Bio, a leading biotechnology company, made an exciting announcement today regarding their upcoming reverse stock split. The company revealed that shares are expected to begin trading on a split-adjusted basis on July 18, 2024. This move symbolizes an i...
Financing Agreement

Senti Bio Secures $8 Million Grant to Advance Clinical Development of Regenerative Therapy

Published Mon, Jul 1 2024 12:06 PM UTC



In a groundbreaking move for the field of regenerative medicine, the California Institute for Regenerative Medicines (CIRM) has announced an $8 million grant to Senti Bio. The generous funding is intended to support the clinical development of SENTI-202, a logic gated CAR-NK cell therapy. This development comes amidst positive financial indicators for Senti Bioscie...
Clinical Study

SENTI-202 Commences Phase 1 Clinical Trial: A Promising Breakthrough in Hematologic Malignancy Treatment

Published Mon, May 13 2024 12:16 PM UTC

CSIMarket.com aims to provide a comprehensive overview of the latest advancements in the field of pharmaceutical research and development. In accordance with this , this article sheds light on a groundbreaking development concerning the commencement of Phase 1 clinical trials for SENTI-202, a novel treatment for relapsed or refractory hematologic malignancies, including Ac...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com